Warp Sciences Launches to Automate Drug Discovery Labs with Robotics

Image: TechCrunch · Source

Warp Sciences, founded by former OpenAI science lead Kevin Weil, aims to revolutionize drug discovery by automating wet-lab tasks with trained robots, backed by a $215M funding round.

Kevin Weil, formerly the science lead at OpenAI, has launched Warp Sciences, a new AI-driven startup focused on automating laboratory work for drug discovery. The company uses robotics trained by human chemists to perform complex and labor-intensive experimental tasks in wet labs, such as synthesizing and testing chemical compounds. This approach promises to accelerate the drug development process by enabling robots to operate continuously without the typical constraints of manual lab work.

Warp Sciences recently secured $215 million in funding at a valuation of $865 million. The funding round was led by Lightspeed with contributions from IVP, Premji Invest, and Lux Capital, signaling strong investor confidence in the startup’s vision. Weil introduced the company and its funding details via the social platform X.

Traditionally, biotech firms have outsourced time-consuming synthesis of thousands of molecule variants to contractors, often in China, such as WuXi AppTec. Warp Sciences aims to reshore this critical drug discovery work within domestic labs to reduce reliance on international supply chains that can be vulnerable to geopolitical disruptions.

A distinctive element of Warp Sciences’ method involves human chemists wearing cameras and sensor gloves to demonstrate lab tasks directly to robots. This hands-on training approach enables the robots to learn precise manipulations required for chemical synthesis and analysis. By digitizing and automating these tasks, the startup expects to increase throughput and reproducibility in experimental workflows.

This robotics-driven automation in wet labs could represent a paradigm shift in pharmaceutical R&D by significantly reducing the time from compound design to testing. Warp Sciences’ innovation addresses a key bottleneck in drug discovery and could enhance the resilience and efficiency of developing new medicines.